Here are the 10-Q quarterly reports from Oncolytics Biotech, Inc. (ONCY) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ONCY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ONCY filings page.
Oncolytics Biotech Inc. reported a larger net loss as it advanced its immunotherapy pelareorep and expanded corporate activities. For the three and six months ended June 30, 2026, net losses were $9,442 and $18,685 versus $5,277 and $9,988 in 2025, driven by higher research and development and general and administrative expenses. R&D reached $8,814 and G&A $9,846 for the six‑month period as the company launched a randomized Phase 2 second‑line metastatic colorectal cancer trial and prepared potential registrational work in anal cancer. Cash and cash equivalents were $4,115, with operations funded mainly through at‑the‑market equity sales raising $14,385 in net proceeds. Management states that current resources, even with equity distribution capacity, are not sufficient to fund planned operations for 12 months, and discloses substantial doubt about the ability to continue as a going concern, indicating a need for additional financing or strategic arrangements.
Oncolytics Biotech Inc. reported a larger quarterly loss and highlighted funding risk as it advances its cancer pipeline. For the three months ended March 31, 2026, net loss widened to $9.2 million, or $0.08 per share, from $4.7 million a year earlier as research and development and general and administrative expenses both roughly doubled.
Cash and cash equivalents were $5.5 million, and operating activities used $7.3 million of cash. Management stated that existing cash, even with access to equity distribution arrangements, is not sufficient to fund planned operations for at least twelve months, raising substantial doubt about the company’s ability to continue as a going concern unless additional financing is secured.
To bolster liquidity, the company raised net proceeds of $7.6 million by selling 7.4 million common shares through at-the-market offerings and later entered a new sales agreement allowing issuances of up to $75 million. Oncolytics continues to focus on pelareorep, its immunotherapy candidate, including a new randomized Phase 2 colorectal cancer trial and Fast Track Designation in RAS‑mutated metastatic colorectal cancer.